Last reviewed · How we verify
ADC189 tablets
ADC189 is an antibody-drug conjugate that targets a specific tumor-associated antigen to deliver cytotoxic payload directly to cancer cells.
ADC189 is an antibody-drug conjugate that targets a specific tumor-associated antigen to deliver cytotoxic payload directly to cancer cells. Used for Solid tumors (specific indication under investigation in Phase 3).
At a glance
| Generic name | ADC189 tablets |
|---|---|
| Sponsor | Jiaxing AnDiCon Biotech Co.,Ltd |
| Drug class | Antibody-drug conjugate (ADC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As an ADC, ADC189 combines a monoclonal antibody with a cytotoxic small molecule linker. The antibody component binds to its target antigen on cancer cells, enabling selective internalization and release of the toxic payload within tumor cells while minimizing systemic exposure. This targeted delivery approach aims to improve efficacy while reducing off-target toxicity compared to conventional chemotherapy.
Approved indications
- Solid tumors (specific indication under investigation in Phase 3)
Common side effects
- Nausea
- Fatigue
- Thrombocytopenia
- Anemia
Key clinical trials
- Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza (PHASE3)
- ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection (PHASE2, PHASE3)
- A Drug-Drug Interaction (DDI) Study of ADC189 With Itraconazole in Healthy, Adult Subjects (PHASE1)
- Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose (PHASE1)
- To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADC189 tablets CI brief — competitive landscape report
- ADC189 tablets updates RSS · CI watch RSS
- Jiaxing AnDiCon Biotech Co.,Ltd portfolio CI